Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fumoleau

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Investigational New Drugs|May 4, 2005
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulamCharlotte van Kesteren, Anthe S Zandvliet, Mats O Karlsson, et al.
Lancet (London, England)|June 11, 2019
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
Oncotarget|October 26, 2016
The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?Marie Eliade, Jeremy Skrzypski, Amandine Baurand, et al.
European Journal of Human Genetics : EJHG|December 5, 2013
Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 geneEmilie Degrolard-Courcet, Joanna Sokolowska, Marie-Martine Padeano, et al.
Oncotarget|October 21, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patientsDavid G Cox, Elsa Curtit, Gilles Romieu, et al.
NPJ Breast Cancer|June 27, 2017
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohortXavier Pivot, Gilles Romieu, Pierre Fumoleau, et al.
Reproductive Biomedicine Online|May 7, 2022
Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivorsManon Mangiardi-Veltin, Clara Sebbag, Christine Rousset-Jablonski, et al.
Breast Cancer Research : BCR|August 24, 2017
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomesElsa Curtit, Xavier Pivot, Julie Henriques, et al.
Nature Communications|July 14, 2016
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancersAnthony Ferrari, Anne Vincent-Salomon, Xavier Pivot, et al.
Ebiomedicine|April 7, 2019
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcomeSuzy Scholl, Marina Popovic, Anne de la Rochefordiere, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Investigational New Drugs|May 4, 2005
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulamCharlotte van Kesteren, Anthe S Zandvliet, Mats O Karlsson, et al.
Lancet (London, England)|June 11, 2019
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
Oncotarget|October 26, 2016
The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?Marie Eliade, Jeremy Skrzypski, Amandine Baurand, et al.
European Journal of Human Genetics : EJHG|December 5, 2013
Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 geneEmilie Degrolard-Courcet, Joanna Sokolowska, Marie-Martine Padeano, et al.
Oncotarget|October 21, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patientsDavid G Cox, Elsa Curtit, Gilles Romieu, et al.
NPJ Breast Cancer|June 27, 2017
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohortXavier Pivot, Gilles Romieu, Pierre Fumoleau, et al.
Reproductive Biomedicine Online|May 7, 2022
Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivorsManon Mangiardi-Veltin, Clara Sebbag, Christine Rousset-Jablonski, et al.
Breast Cancer Research : BCR|August 24, 2017
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomesElsa Curtit, Xavier Pivot, Julie Henriques, et al.
Nature Communications|July 14, 2016
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancersAnthony Ferrari, Anne Vincent-Salomon, Xavier Pivot, et al.
Ebiomedicine|April 7, 2019
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcomeSuzy Scholl, Marina Popovic, Anne de la Rochefordiere, et al.
Pageof 11